Mesoblast (MEOBF) Accounts Payables (2015 - 2026)
Mesoblast's (MEOBF) quarterly Accounts Payables came in at $46.8 million in Q2 2026, up 145.29% year-over-year from $19.1 million in Q2 2025, and up 39.4% quarter-over-quarter from $33.6 million in Q4 2025.
Analysis
Mesoblast (MEOBF) Accounts Payables (2015 - 2026) Analysis & Trends
Mesoblast has disclosed Accounts Payables across 12 years of filings, most recently posting $46.8 million for Q2 2026.
- In Q2 2026, Accounts Payables rose 145.29% year-over-year to $46.8 million; the TTM figure through Jun 2026 stood at $46.8 million (up 145.29% YoY), while the FY2026 annual figure was $46.8 million, up 145.29% from the prior year.
- Accounts Payables came in at $46.8 million for Q2 2026 at Mesoblast, up from $33.6 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $46.8 million in Q2 2026 to a low of $7.1 million in Q2 2024.
- Average Accounts Payables over 5 years is $21.1 million, with a median of $19.6 million recorded in 2023.
- Year-over-year, Accounts Payables tumbled 64.9% in 2024 and surged 183.1% in 2025.
- Over 5 years, Accounts Payables stood at $23.0 million in 2022, then tumbled by 53.2% to $10.8 million in 2023, then advanced by 10.22% to $11.9 million in 2024, then surged by 183.1% to $33.6 million in 2025, then soared by 39.4% to $46.8 million in 2026.
- Per Business Quant data, the three most recent Accounts Payables figures were $46.8 million in Q2 2026, $33.6 million in Q4 2025, and $19.1 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn | 6.54 Mn |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - | 11.31 Mn |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn | 26.21 Mn |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | 77.30 Mn |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | 4.98 Mn |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - | 13.10 Mn |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | 5.30 Mn |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | 50.98 Mn |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn | 20.61 Mn |
| 10 | Mesoblast | 246.02 Mn | 143.11 Mn | - | 46.81 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 46.81 Mn |
| Dec 31, 2025 | 33.58 Mn |
| Jun 30, 2025 | 19.08 Mn |
| Dec 31, 2024 | 11.86 Mn |
| Jun 30, 2024 | 7.07 Mn |
| Dec 31, 2023 | 10.76 Mn |
| Jun 30, 2023 | 20.15 Mn |
| Mar 31, 2023 | 20.97 Mn |
| Dec 31, 2022 | 22.99 Mn |
| Sep 30, 2022 | 17.66 Mn |
| Jun 30, 2022 | 23.08 Mn |
| Mar 31, 2022 | 18.98 Mn |
| Dec 31, 2021 | 20.92 Mn |
| Sep 30, 2021 | 16.26 Mn |
| Jun 30, 2021 | 19.60 Mn |
| Mar 31, 2021 | 24.28 Mn |
| Dec 31, 2020 | 28.61 Mn |
| Sep 30, 2020 | 27.60 Mn |
| Jun 30, 2020 | 24.97 Mn |
| Mar 31, 2020 | 19.48 Mn |